Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Biomaterials. 2020 Mar 4;243:119935. doi: 10.1016/j.biomaterials.2020.119935

Figure 3. Suppression of Choroidal Neovascularization (CNV) at Bruch’s Membrane Rupture Sites for 18 Weeks after Suprachoroidal Injection of PLGA- Acriflavine (PLGA-ACF) Microparticles (MPs).

Figure 3.

Brown Norway rats were given a suprachoroidal injection of 6 μg of PLGA-ACF MPs in one eye and empty PLGA MPs in the other eye. (A) Two weeks after injection, a frozen ocular section showed ACF fluorescence in the retina and choroid on the side of the eye that had been injected. (B) A high magnification fluorescence microscopy image (left side) and a light micrograph of the same section stained with Hoechst (right side) showed PLGA-ACF MPs in the choroid (arrows) and bright fluorescence from ACF in retinal pigmented epithelium (RPE), photoreceptor outer segments (OS) and inner segments (IS), outer nuclear layer (ONL) and inner nuclear layer (INL) of the retina. There was weak fluorescence from ACF in the sclera. At 2, 4, 8, 12, and 16 weeks after injection, Bruch’s membrane was ruptured by laser photocoagulation in each eye. Two weeks after rupture of Bruch’s membrane, choroidal flat mounts were stained with FITC- Griffonia simplicifolia lectin. At each time point (weeks between MP injection and measurement of CNV), the area of CNV at Bruch’s membrane rupture sites appeared smaller in eyes that had been injected with PLGA-ACF MPs (C). Image analysis showed a significant reduction in mean (± SEM) area of CNV in eyes injected with PLGA-ACF MPs compared with those injected with empty PLGA MPs at all time points. N is the number of eyes evaluated in each group (** p<0.01, * p<0.05 by unpaired t- test).